Earnings ·
Nautilus Biotechnology reported financial results for the quarter ended June 30, 2026, recognizing its first revenue…
NAUTNautilus Biotechnology, Inc.
Nautilus Biotechnology reported financial results for the quarter ended June 30, 2026, recognizing its first revenue of $0.2 million from grant activities and its first Iterative Mapping Early Access Program customer. Operating expenses decreased 7% to $15.9 million, resulting in a net loss of $14.5 million compared to $15.0 million in the prior year period. The company holds $129.2 million in cash, cash equivalents, and investments. Management announced a strategic realignment to accelerate proteoform applications, with the Voyager Platform launch expected in early 2027 and consumable kits available by mid-2027. The Broadscale Portfolio timeline remains undetermined due to performance issues. Nautilus Biotechnology operates in the life sciences industry, developing a single-molecule proteome analysis platform.